Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging

Current Neurology and Neuroscience Reports

Volumn 9, Issue 3, 2009, Pages 241-246

  Clarke, Jennifer L ^a   Chang, Susan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; CEDIRANIB; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; TEMOZOLOMIDE;

ADJUVANT THERAPY; BRAIN BLOOD VOLUME; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER PSEUDOPROGRESSION; CANCER PSEUDORESPONSE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTRAST ENHANCEMENT; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE;

EID: 64649085454     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-009-0035-4     Document Type: Review

References (28)

1. Stupp RR, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
2. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8:1277-1280.
3. Finn MA, Blumenthal DT, Salzman KL, Jensen RL: Transient postictal MRI changes in patients with brain tumors may mimic disease progression. Surg Neurol 2007, 67:246-250.
4. Ulmer S, Braga TA, Barker FG II, et al.: Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology 2006, 67:1668-1670.
5. Chamberlain M, Glantz M, Chalmers L, et al.: Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007, 82:81-83.
6. Taal W, Brandsma D, de Bruin HG, et al.: Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008, 113:405-410.
7. Brandes AA, Franceschi E, Tosoni A, et al.: MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008, 26:2192-2197.
8. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
9. Prados MD, Chang SM, Butowski N, et al.: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009, 27:579-584.
10. Mullins ME, Barest GD, Schaefer PW, et al.: Radiation necrosis versus glioma recurrence: Conventional MR imaging clues to diagnosis. AJNR Am J Neuroradiol 2005, 26:1967-1972.
11. Kumar AJ, Leeds NE, Fuller GN, et al.: Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000, 217:377-384.
12. Hein PA, Eskey CJ, Dunn JF, Hug EB: Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: Tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 2004, 25:201-209.
13. Hu LS, Baxter LC, Smith KA, et al.: Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: Direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009, 30:552-558.
14. Sugahara T, Korogi Y, Tomiguchi S, et al.: Posttherapeutic intraaxial brain tumor: The value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000, 21:901-909.
15. Shimizu H, Kumabe T, Tominaga T, et al.: Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. AJNR Am J Neuroradiol 1996, 17:737-747.
16. Vigneron D, Bollen A, McDermott M, et al.: Threedimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. Magn Reson Imaging 2001, 19:89-101.
17. Chen W: Clinical applications of PET in brain tumors. J Nucl Med 2007, 48:1468-1481.
18. Ricci P, Karis J, Heiserman J, et al.: Differentiating recurrent tumor from radiation necrosis: Time for re-evaluation of positron emission tomography? AJNR Am J Neuroradiol 1998, 19:407-413.
19. Terakawa Y, Tsuyuguchi N, Iwai Y, et al.: Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008, 49:694-699.
20. Chen W, Cloughesy T, Kamdar N, et al.: Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18FFDG. J Nucl Med 2005, 46:945-952.
21. Xiangsong Z, Weian C: Differentiation of recurrent astrocytoma from radiation necrosis: A pilot study with 13N-NH3 PET. J Neurooncol 2007, 82:305-311.
22. Vredenburgh JJ, Desjardins A, Herndon JE II, et al.: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13:1253-1259.
23. Vredenburgh JJ, Desjardins A, Herndon JE II, et al.: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-4729.
24. Cloughesy TF, Prados MD, Wen PY, et al.: A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) [abstract 2010b]. J Clin Oncol 2008, 26(Suppl).
25. Pope WB, Lai A, Nghiemphu P, et al.: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006, 66:1258-1260.
26. Batchelor TT, Sorensen AG, di Tomaso E, et al.: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
27. Norden AD, Young GS, Setayesh K, et al.: Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70:779-787.
28. Raymond E, Brandes AA, Dittrich C, et al.: Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 2008, 26:4659-4665.